PharmaBlock Sciences (Nanjing), Inc.

XSEC:300725 Stock Report

Market Cap: CN¥7.1b

PharmaBlock Sciences (Nanjing) Past Earnings Performance

Past criteria checks 1/6

PharmaBlock Sciences (Nanjing) has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 18.3% per year. PharmaBlock Sciences (Nanjing)'s return on equity is 6%, and it has net margins of 11.2%.

Key information

1.7%

Earnings growth rate

0.5%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate18.3%
Return on equity6.0%
Net Margin11.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How PharmaBlock Sciences (Nanjing) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300725 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,562175249126
30 Jun 241,626182252140
31 Mar 241,719189259155
31 Dec 231,725197263169
30 Sep 231,701219265180
30 Jun 231,704275271189
31 Mar 231,642301268189
01 Jan 231,595314256168
30 Sep 221,483294240154
30 Jun 221,315258211135
31 Mar 221,251488184112
31 Dec 211,202487177114
30 Sep 211,200484171115
30 Jun 211,184478161103
31 Mar 211,137226167103
31 Dec 201,02218415791
30 Sep 2092317714477
30 Jun 2083117013078
31 Mar 2068114711172
31 Dec 1966215210069
30 Sep 196031578766
30 Jun 195581498756
31 Mar 195311477950
31 Dec 184781337944
30 Sep 184171097537
30 Jun 18362896143
31 Mar 18319756534
31 Dec 17273676225
30 Sep 17244626617
30 Jun 1721944880
31 Mar 1719637850
31 Dec 1618836820
30 Sep 1618330810
30 Jun 1617731540
31 Mar 1615625470
31 Dec 1513620590
31 Dec 147722250
31 Dec 135918190

Quality Earnings: 300725 has a large one-off gain of CN¥64.8M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300725's current net profit margins (11.2%) are lower than last year (12.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300725's earnings have grown by 1.7% per year over the past 5 years.

Accelerating Growth: 300725's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300725 had negative earnings growth (-19.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 300725's Return on Equity (6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 00:27
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaBlock Sciences (Nanjing), Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.
Yuan Yuan SunIndustrial Securities Co. Ltd.